Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference scheduled for Monday, June 10, 2024, at 8:00 a.m. (EDT) in Miami. The event will be webcast live and can be accessed via Investor.Incyte.com, with a replay available for 30 days.
Incyte (Nasdaq: INCY) will present multiple abstracts from its oncology portfolio at the 2024 ASCO Annual Meeting (May 31 – June 4) and EHA2024 Congress (June 13-16). Key studies include:
ASCO: INCB099280 - Phase 1 Small-Molecule PD-L1 inhibitor study, INCB057643 - Phase 1 BET inhibitor study.
EHA: Ruxolitinib - Multiple studies on Polycythemia Vera and Myelofibrosis, Zilurgisertib - ALK2 inhibitor studies, INCB160058 - Novel therapy for JAK2V617F mutant Myeloproliferative Neoplasms, Axatilimab - Graft-Versus-Host Disease study, Pemigatinib - Phase 2 study on Myeloid/Lymphoid Neoplasms, Tafasitamab - CD19 expression in Diffuse Large B-Cell Lymphoma.
These presentations highlight Incyte's commitment to developing new cancer treatments.
Incyte announced a $2.0 billion share repurchase authorization, with a Dutch Auction tender offer to repurchase up to $1.672 billion of outstanding common shares. The offer reflects confidence in the company's future outlook, product portfolio, and clinical pipeline. A separate stock purchase agreement with Baker Entities will repurchase up to $328.0 million of common stock, enabling them to maintain their ownership level. The tender offer, expiring on June 10, 2024, allows stockholders to tender shares within a price range for repurchase.
Incyte (Nasdaq:INCY) will be presenting at the Bank of America Securities 2024 Health Care Conference on May 15, 2024, in Las Vegas. The presentation will be webcast live and available for replay for 30 days.
Incyte reports total revenues of $881 million in Q1'24, up 9% Y/Y, with Jakafi® net product revenues at $572 million, Opzelura® at $86 million, and plans to acquire Escient Pharmaceuticals. The company made progress with clinical pipeline and key agreements for drug development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.